{"id":"test-group-l-oxiracetam-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"L-oxiracetam is a pyrrolidone derivative that is believed to modulate membrane properties and enhance synaptic plasticity. It may improve oxygen utilization and energy metabolism in the brain, supporting neuroprotection and cognitive enhancement. The exact molecular mechanisms remain incompletely characterized but likely involve membrane stabilization and enhancement of neuronal signaling.","oneSentence":"L-oxiracetam enhances neuronal membrane fluidity and facilitates neurotransmitter function, potentially improving cognitive and neurological outcomes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:38:16.383Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cognitive impairment and memory disorders"},{"name":"Age-related cognitive decline"},{"name":"Cerebrovascular insufficiency"}]},"trialDetails":[{"nctId":"NCT04205565","phase":"PHASE3","title":"Study on Clinical Effectiveness of L-Oxiracetam Injection","status":"UNKNOWN","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2019-09-30","conditions":"Craniocerebral Injury","enrollment":591}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Test group: L-oxiracetam Injection","genericName":"Test group: L-oxiracetam Injection","companyName":"Nanjing Yoko Biomedical Co., Ltd.","companyId":"nanjing-yoko-biomedical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-oxiracetam enhances neuronal membrane fluidity and facilitates neurotransmitter function, potentially improving cognitive and neurological outcomes. Used for Cognitive impairment and memory disorders, Age-related cognitive decline, Cerebrovascular insufficiency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}